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Abstract 
The performance of ferrate(VI) in treating sulfamethoxazole (SMX), 
diclofenac (DCF), carbamazepine (CBZ) and bezafibrate (BZF) in test solutions 
containing the four compounds was investigated. A series of jar-test experiments was 
performed on a bench-scale at pH 6–9 and at a ferrate(VI) dose of 1–5 mg Fe/L. The 
results suggested that ferrate(VI) can effectively remove SMX, DCF and CBZ from 
the test solutions, with greater than 80% removal under optimum conditions. However, 
the removal efficiency of BZF was very low, less than 25% under the studied 
conditions. Increasing the dose of ferrate(VI) improved the treatment performance, 
while the influence of solution pH on ferrate(VI) performance varied among the 
different target compounds. Ferrate(VI) demonstrated the highest reactivity with SMX 
at pH 8 and pH 9 (20 °C), with apparent second-order rate constants of 360 ± 17 M?1 
s?1 and 1.26 ± 0.02 M?1 s?1, respectively. However, BZF showed the lowest removal 
by ferrate(VI) with the smallest rate constants (less than 0.5 M?1 s?1) at pH 8 and pH 9. 
Furthermore, a number of oxidation products (OPs) of SMX, DCF and CBZ during 
ferrate(VI) oxidation were detected by liquid chromatography and mass spectrometry 
(LC-MS), and their degradation pathways were tentatively proposed. No OPs of BZF 
were detected during ferrate(VI) oxidation. 
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1. Introduction 
The detection of a great variety of pharmaceuticals at trace levels (ng/L–?g/L) in 
the aquatic environment has led to increasing public concern [1-3]. The long-term 
effects of these trace pharmaceutical residues on human beings and the eco-system are 
still not clear. Nevertheless, worries of potential adverse effects remain [4, 5]. 
Therefore, studies investigating the removal of the pharmaceuticals from water and 
wastewater have been carried out recently [6, 7], mainly focusing on ozonation and 
advanced oxidation processes (AOPs). Ozone, as a selective oxidant, tends to have 
great capability in oxidising pharmaceuticals containing electron-rich moieties (ERMs) 
(e.g. sulfamethoxazole) rather than those without ERMs (e.g. ibuprofen) [8, 9]. On the 
other hand, hydroxyl radicals based AOPs have remarkable capability to degrade 
nearly all target pollutants with very high rate constants (up to 109 M?1 s?1) [10] while 
their applications in natural and wastewater treatment still face several challenges 
such like co-existing compounds (e.g. NOMs) and radical scavengers (e.g. CO32? and 
HCO3?) [11, 12]. 
Ferrate(VI) salt is a promising dual-functional chemical for water and wastewater 
treatment and can achieve the reduction of a wide range of organic and inorganic 
pollutants in wastewater [13-15]. Moreover, unlike ozonation, ferrate(VI) does not 
generate bromate, a potentially carcinogenic by-product, in treating bromide-
containing waters [16]. Several studies examining the decontamination of 
pharmaceuticals in test solutions and pharmaceutical-spiked wastewater effluents by 
ferrate(VI) have been published [17-21]. The results demonstrated that ferrate(VI) 
possessed a great capability in treating pharmaceutical compounds with ERMs, e.g. 
ciprofloxacin, with removal efficiencies higher than 85%. The second-order rate 
constants between ferrate(VI) and some pharmaceuticals were also determined (e.g. 
higher than 103 M?1 s?1 for sulfamethoxazole and triclosan).  However, little 
information is available with regard to the optimisation of ferrate(VI) treatment for 
future practical application, such as the influence of the solution pH and the ferrate(VI) 
dosage. Furthermore, even though oxidation products (OP) and degradation pathways 
for the oxidation of several pharmaceuticals by ferrate(VI) have been proposed [22, 
23], a data-base containing similar information on many other pharmaceuticals needs 
to be established. 
In this study, ferrate(VI)’s performance and degradation pathways in treating 
selected pharmaceuticals were investigated. The target compounds chosen for the 
experiments were sulfamethoxazole (SMX), diclofenac (DCF), carbamazepine (CBZ) 
and bezafibrate (BZF), and their basic properties are presented in Table S1 of the 
Supplementary Material (SM). These compounds belong to different therapeutic 
groups, namely antibiotics (SMX), antiphlogistics (DCF), antiepileptics (CBZ) and 
lipid regulators (BZF), and have been found widely in the aquatic environment with 
concentrations up to hundreds of ng/L [24, 25]. The objectives of this study were 1) to 
investigate the influence of solution pH and ferrate(VI) dosage on the removal of the 
selected pharmaceuticals; 2) to determine the rate constants of the reaction of 
ferrate(VI) with target compounds; and 3) to identify OPs and propose degradation 
pathways of four target pharmaceuticals during ferrate(VI) oxidation. To our best 
knowledge, this is the first study to investigate the removal of BZF by ferrate(VI) and 
identify the OPs of DCF during ferrate(VI) treatment.   
2. Materials and methods 
2.1. Chemicals and reagents 
Sulfamethoxazole (SMX), diclofenac sodium (DCF), carbamazepine (CBZ) and 
bezafibrate (BZF) of analytical grade or above were purchased from Sigma-Aldrich 
(UK). Potassium ferrate(VI) (purity higher than 90%) was also obtained from Sigma-
Aldrich (UK). Other chemicals and solvents were supplied by Fisher Scientific (UK). 
All chemicals and solvents were used without further purification. Experimental water 
was generated by an Elga PureLab Option–R 7/15 pure water system (Veolia Water, 
France). Stock solutions of ferrate(VI) were freshly prepared by dissolving solid 
K2FeO4 in 0.0125 M Na2B4O7·10H2O/0.005 M HCl buffer solution at pH 9.0 to make 
a ferrate(VI) concentration of 1 g/L as Fe. 
Two approaches were utilised to prepare stock solutions of target pharmaceuticals 
for different purposes. (1) Jar test experiments and identification of OPs: stock 
solutions of target compounds were prepared in methanol at 100 mg/L. (2) Kinetic 
studies: stock solutions of DCF and SMX, which have high aqueous solubility (higher 
than 500 mg/L at experimental temperature), were prepared by directly dissolving 
solid chemicals in pure water. On the other hand, stock solutions of CBZ and BZF 
were prepared in acetonitrile at the appropriate concentrations to yield a 2% (v/v) 
percentage of acetonitrile in the final diluted test solutions. It has been reported that 2% 
acetonitrile in solution exerts little influence on reactions with ferrate(VI) [26]. 
2.2. Jar test experiments 
Test solutions (one litre each) with two levels of concentrations for each 
compound, 100 and 10 ?g/L, were prepared in buffer solutions at pH 6–9, the pH 
range that is usually applied in practical water and wastewater treatment. The buffer 
solutions employed were 0.05 M KH2PO4/0.005–0.05 M NaOH for pH 6–8 and 
0.0125 M Na2B4O7·10H2O/0.005 M HCl for pH 9. 
A series of jar test experiments was carried out with a six-unit stirrer (Kemira 
flocculator 2000, Kemwater) under the following protocol: fast mixing for 1 min at 
400 rpm; slow mixing for 60–180 min at 40 rpm; and then sedimentation for 60 min. 
The ferrate(VI) dose applied was 0–5 mg/L as Fe. All experiments were conducted in 
duplicate. 
A specified amount of the supernatant was filtered sequentially with 1.2 ?m glass 
fibre filters (Fisher Scientific, UK) and 0.45 ?m membrane filters (Millipore, USA) 
after sedimentation. The solution pH of the filtrate was adjusted to 2.5 by 1 M H2SO4 
and then subjected to solid phase extraction (SPE) and further analysis by high 
performance liquid chromatography (HPLC)-UV.  
2.3. Kinetic studies 
Kinetic studies of ferrate(VI) with the target compounds were performed with the 
pharmaceuticals in excess (pseudo-first-order condition). The room temperature was 
20±2 °C throughout the kinetic studies. A low ferrate(VI) dosage (2.5–10 ?M) was 
applied to lower the self-decomposition rate of ferrate(VI). The rate constants were 
determined at pH 8 and pH 9. The reaction was started by dosing ferrate(VI) solution 
into 500 mL buffered test solutions under stirring at 200 rpm. Aliquots of the reacting 
solution were then quenched with ABTS solution at certain time intervals. The 
remaining ferrate(VI) was measured by the ABTS method at 415 nm [27] using a 
DR3900 VIS spectrophotometer (Hach-Lange, USA). For the details of the ABTS 
method, please see Text S1 of the SM. The kinetic experiments were performed in 
triplicate for each condition. 
2.4. Identification of oxidation products 
Test solutions containing 10 mg/L of the target compounds were prepared 
separately in pure water. Two levels of ferrate(VI) doses (5 mg/L and 10 mg/L as Fe) 
were applied to the stirred test solutions at 200 rpm to investigate whether the higher 
dose (10 mg/L) would improve the formation of OPs. The solution pH was carefully 
adjusted by 0.01 M H2SO4 or 0.02 M NaOH to yield a final pH of 6.5–7.5. A selected 
portion of the solution was filtered by 0.45 ?m Puradisc syringe filters (Whatman, 
USA) after the reaction was completed. Then, the solution pH was adjusted to 2.5 
using 1 M H2SO4 for further liquid chromatography (LC)-mass spectrometry (MS) 
analysis. The experiments were operated in parallel under identical conditions. 
2.5. Analytical methods 
The remaining pharmaceutical compounds present in the treated test solutions 
were enriched by solid phase extraction (SPE). The SPE cartridges employed were 
Strata-X 1 g/12 mL giga tubes (Phenomenex, UK). Generally, the extraction method 
consisted of the following steps: (1) condition: 6 mL methanol; (2) equilibrate: 6 mL 
water; (3) load samples: flow desired amount of water samples under vacuum at a 
flow rate of 5–10 mL/min; (4) wash: 2 × 6 mL water; (5) dry: 15 min under gentle 
nitrogen flow; and (6) elute: 2 × 6 mL 2:49:49 (v/v/v) formic 
acid/methanol/acetonitrile. The eluents were evaporated to dryness at 50 °C using a 
DB-2A Dri-Block (Techne, UK) and then re-constituted to 1 mL by 50:50 (v/v) 
methanol/water. The final enriched samples were filtered with 0.45 ?m Puradisc 
syringe filters (Whatman, USA) and subjected to HPLC analysis. 
An Agilent 1100 system (Agilent Technologies, USA) with a diode array detector 
(DAD) was employed for the measurement of target compounds. The column utilised 
for the separation of compounds was a 2.6 ?m, 100 mm × 2.10 mm reversed phase 
Kinetex XB-C18 column (Phenomenex, UK). The column was kept at 25 °C and 
eluted by acetonitrile (Solvent A) and 0.1% formic acid in pure water (Solvent B) at a 
flow rate of 0.2 mL/min. The elution was initiated with 20% solvent A. Then, the 
percentage of solvent A was increased to 45% over the next 6 min, held at this 
percentage for 15 min and finally lowered to 20% in 1 min. The DAD wavelengths 
for BZF, SMX, DCF and CBZ detection were pre-determined and set at 230 nm, 270 
nm, 280 nm and 290 nm, respectively. The method was validated and has been 
published elsewhere [28].  
An Agilent 1100 HPLC plus a Bruker Daltonics Esquire 3000 ion trap mass 
spectrometer (MS) were employed to identify the OPs of target compounds treated by 
ferrate(VI). The separation was achieved by an Atlantis C18 column (3 ?m, 150 mm × 
2.1 mm, Waters, USA) using a gradient of acetonitrile (Solvent A)/ ammonium 
formate and formic acid in water (pH 3.5, Solvent B) at 0.2 mL/min. Solvent A was 
initially 1% and was maintained at this percentage for 2 min. Then, the percentage 
was increased to 30% in the next 1 min and stayed at 30% until 20 min. After that, the 
percentage of solvent A was gradually increased from 20% to 99% in 13 min, 
maintained at the same level for 9 min, and finally decreased back to 1% in 1 min. All 
of the target compounds were identified by full MS scans in positive and/or negative 
electrospray ionisation (ESI) mode. 
3. Results and discussion 
3.1. Removal of selected pharmaceuticals from test solutions 
3.1.1. Initial concentrations of 100 ?g/L 
The removal efficiencies of target compounds with initial concentrations of 
100 ?g/L by ferrate(VI) are presented in Fig. 1. Generally, the performance of 
ferrate(VI) varied greatly among the different target compounds. 
 Fig. 1. The effect of ferrate(VI) dose and solution pH on the removal of 
pharmaceuticals from a mixed compound solution (initial concentration of 100 ?g/L) 
(a) BZF; (b) SMX; (c) DCF; and (d) CBZ. 
 
For BZF, the removal efficiencies by ferrate(VI) under all conditions were less 
than 25% (Fig. 1a). The results demonstrated that raising the ferrate(VI) dose from 1 
mg/L to 5 mg/L improved the BZF reduction for all pH conditions. In terms of pH 
influence, the BZF removal at pH 7 and pH 8 was greater than that at pH 6 and pH 9. 
Specifically, the greatest BZF removal was observed at pH 8, where 15.3–21.4% of 
BZF was reduced by ferrate(VI). On the other hand, the BZF removal at pH 6 was the 
lowest, with only 5.6% reduction achieved at 5 mg/L ferrate(VI). 
For SMX, an increase in ferrate(VI) dose also improved the performance for 
all pH conditions (Fig. 1b). At pH 9, the SMX removal increased significantly with 
increasing ferrate(VI) dose, from 12.9% at 1 mg/L to 85.8% at 5 mg/L. On the other 
hand, at pH 6–8, there was no great improvement in SMX removal with increasing 
ferrate(VI) dose, especially when the dose exceeded 2 mg/L. However, the overall 
SMX removal by ferrate(VI) at pH 6–8 was better than that at pH 9. Specifically, the 
removal percentages were all above 50% at pH 6–8 and at the lowest dose, 1 mg/L. 
Then, the removal of SMX gradually increased with rising ferrate(VI) dose, reaching 
approximately 90% SMX reduction at 5 mg/L.  
Increasing ferrate(VI) dose improved DCF removal significantly at pH 6–9 
(Fig. 1c). For instance, when the solution pH was 6, the removal of DCF by ferrate(VI) 
was only 4.9% at 1 mg/L, and then increased with rising ferrate(VI) dose by 
approximately 25% for the addition of every 1 mg/L until the dose reached 4 mg/L. 
Upon further increase in the ferrate(VI) from 4 mg/L to 5 mg/L, the DCF removal 
rose slightly to 79%. Similar patterns of DCF removal with increasing ferrate(VI) 
dose were also noticed at pH 7–9. In terms of the effect of solution pH, at relatively 
high doses (4–5 mg/L), the DCF removal was not affected by the solution pH, while 
at relatively low doses (1–3 mg/L), the removal efficiencies of DCF at pH 6 were 
lower than those at pH 7–9 by 5–20%. Generally, more than 50% of DCF could be 
reduced in the pH range 6–9 when the ferrate(VI) dose reached 3 mg/L. 
As for CBZ, both solution pH and ferrate(VI) dose exerted a significant 
influence on its reduction (Fig. 1d). The influence of the ferrate(VI) dose on the CBZ 
removal at pH 8 and 9 was much stronger than that at pH 6 and 7. For instance, when 
the solution pH was 9, CBZ removal increased significantly from 23.7% at 1 mg/L to 
99.1% at 5 mg/L. On the other hand, at pH 6 and 7, the CBZ reduction was increased 
by approximately 45% with an increase in the ferrate(VI) dose from 1 mg/L to 5 mg/L. 
In addition, the solution pH significantly affected CBZ removal. CBZ removal at pH 
8–9 was better than that at pH 6–7. In particular, at pH 9, when the ferrate(VI) dose 
reached 4 mg/L or above, the CBZ reduction was higher than 90%. On the other hand, 
the worst performance was observed at pH 6, where the CBZ reduction was less than 
50% for all ferrate(VI) doses. 
 Comparing the reduction of all four compounds, the performance of ferrate(VI) 
in treating BZF was the least efficient. The removal rates of the other three 
compounds could exceed 80% under specific conditions. Generally, a feasible 
operating condition was to adjust solution pH at 7–9 and use doses higher than 4 mg/L 
as Fe in applying ferrate(VI) oxidation to achieve at least 50% of SMX, DCF and 
CBZ reduction from test solutions with initial concentrations of 100 ?g/L.  
 
3.1.2. Initial concentrations of 10 ?g/L 
The results of removing target compounds with initial concentrations of 10 
?g/L from test solutions by ferrate(VI) were significantly different from those 
obtained with an initial concentrations of 100 ?g/L, except for BZF. As shown in Fig. 
2a, the reduction of BZF was low and less than 25% under all conditions. Raising the 
ferrate(VI) dose slightly improved BZF removal at pH 8 and 9. For instance, at pH 9, 
the reduction of BZF by ferrate(VI) was less than 15% at ferrate(VI) doses of 1 mg/L 
and 2 mg/L, and then slightly increased to over 20% when the ferrate(VI) dose 
reached 3 mg/L. Additionally, at pH 7 and 8, the removal efficiencies peaked at a 
ferrate(VI) dose of 3 mg/L, with 11.3% and 20.6% BZF removal, respectively.  
 Fig. 2. The effect of ferrate(VI) dose and solution pH on the removal of 
pharmaceuticals from a mixed compound solution (initial concentrations 10 ?g/L) (a) 
BZF; (b) SMX; (c) DCF; and (d) CBZ. 
 
For SMX, the overall removal efficiencies by ferrate(VI) were higher than 60% for all 
solution pH and ferrate(VI) doses (Fig. 2b), with small variations for different 
conditions. In addition, SMX removal at pH 9 appeared to be the best, though there 
was a slight drop in SMX removal when the ferrate(VI) dose was increased from 4 
mg/L to 5 mg/L. For DCF, increasing the ferrate(VI) dose improved the treatment 
performance to some extent; however,  when the solution pH was 6, the removal 
efficiencies of DCF by ferrate(VI) remained at approximately 80% (Fig. 2c). Upon 
raising the ferrate(VI) dose, a significant increase in DCF removal was observed at 
solution pH 9. In terms of pH influence, the DCF removal at pH 6–7 appeared to be 
better than that at pH 8–9, especially at ferrate(VI) doses of 2–4 mg/L. Nonetheless, 
the overall removal efficiency of DCF removal could exceed 50% across the 
examined pH and dose ranges. Moreover, ferrate(VI) oxidation exhibited excellent 
performance for the removal of CBZ from the solution with an initial concentration of 
10 ?g/L; all reduction rates were higher than 95% (Fig. 2d). 
For the removal of target compounds with initial concentrations of 10 ?g/L, 
CBZ removal was the highest for all operating pH values. On the other hand, BZF 
removal was the lowest at pH 6–9. There were no significant removal differences 
between DCF and SMX. For both SMX and DCF, ferrate(VI) showed good treatment 
performance, with removal efficiencies higher than 50% for all applied conditions. 
The results of using ferrate(VI) to treat two test solutions showed that SMX, 
CBZ and DCF were effectively removed at pH 6–9; their removal efficiencies could 
exceed 80% under optimum conditions. However, the low removal rates of BZF 
suggested that ferrate(VI) is a selective oxidant. Ferrate(VI) is capable of oxidising 
pollutants containing ERMs [29, 30], while SMX (aniline), DCF (amine) and CBZ 
(olefin) all contain ERMs in their structures. On the other hand, BZF has a carboxylic 
group, which is an electron-withdrawing functional group and can depress the 
reactivity of aromatic rings with ferrate(VI) [21]. Thus, the low reactivity of 
ferrate(VI) with BZF may be attributed to the carboxylic functional group in its 
structure. 
 
3.2. Rate constants 
The rate law for the reaction of ferrate(VI) with target compounds can be 
written as follows: 
 
?d[Fe(VI)]/dt = kapp[Fe(VI)]m[X]n  (1) 
Where [Fe(VI)] and [X] are the total molar concentrations of all species of ferrate(VI) 
and the target compounds, respectively; kapp is the apparent rate constant of the 
reaction between ferrate(VI) and the target compounds; m and n are the orders of the 
reactions with respect to each reactant. Under pseudo-first-order conditions, Eq. (1) 
can be re-written as follows: 
 
?d[Fe(VI)]/dt = k’[Fe(VI)]m  (2) 
Where k’ = kapp[X]n. 
Rate constants for the reactions of ferrate(VI) with selected pharmaceuticals 
were determined under pseudo-first-order conditions at pH 8.0 and 9.0 at 20? °C. The 
concentrations of the target compounds were at least ten times higher than that of 
ferrate(VI). Thus, the reaction could be regarded as first-order with respect to [Fe(VI)]. 
The experimental results also confirmed this first-order relationship with respect to 
[Fe(VI)]. Taking the reaction of ferrate(VI) with SMX as an example, as shown in Fig. 
S1 of SM, the plot of ferrate(VI) degradation versus reaction time fitted nicely to a 
single exponential decay curve with a good coefficient of correlation (0.994), which 
suggests that the reaction is first-order with respect to [Fe(VI)] [31]. In this case, m=1 
and Eq. (2) could be re-written as 
 
?d[Fe(VI)]/dt = k’[Fe(VI)]  (3) 
 
Pseudo-first-order rate constants (k’) were determined for different 
concentrations of the target compounds. In addition, the k’ values were corrected for 
the ferrate(VI) self-decay rate in buffered solutions under the same pH condition (Text 
S2 and Table S2, SM). Again using SMX as an example (Fig. S2, SM), the k’ values 
obtained at different concentrations of SMX showed a linear relationship to [SMX], 
which indicates that the reaction between ferrate(VI) and SMX is also first-order with 
respect to the concentration of SMX, and therefore n=1. Then, the overall reaction can 
thus be written as 
 
?d[Fe(VI)]/dt = kapp[Fe(VI)][X]  (4) 
 
The apparent second-order rate constant (kapp) for the reaction was then 
determined as the slope of the plot k’ versus [SMX]. The kapp values of the reactions 
for ferrate(VI) with other target compounds were determined by following the same 
procedure mentioned above with respect to SMX and are summarised in Table 1.  
 
Table 1 
Apparent second-order rate constants for the reactions of ferrate(VI) with selected 
pharmaceuticals. 
 
Ferrate(VI) showed different reactivity with the four target compounds. 
Ferrate(VI) demonstrated moderate reactivity with SMX, CBZ and DCF at pH 9, with 
kapp values of 1.26 ± 0.02, 1.09 ± 0.11 and 0.60 ± 0.01 M?1 s?1, respectively. Lowering 
the solution pH improved their reactivity with ferrate(VI), especially for SMX, whose 
kapp was increased to 360 ± 17 M?1 s?1 at pH 8. This phenomenon was in agreement 
with many other studies [32, 33], which could be explained by considering the acid-
base species of ferrate(VI), as given below [34]: 
 
H3FeO4+ ? H+ + H2FeO4  pKa1=1.6 
H2FeO4 ? H+ + HFeO4-  pKa2=3.5 
HFeO4- ? H+ + FeO42-  pKa3=7.3 
 
Among all of the species of ferrate(VI), HFeO4- has been regarded as the most 
reactive species in many reactions [31, 35]. Thus, with the increase of the fraction of 
HFeO4- from pH 9 to pH 8, the reactivity of ferrate(VI) with the target compounds 
improved.  
On the other hand, the reactivity of ferrate(VI) with BZF was very low. The k’ 
values of BZF at pH 8 and pH 9 were very close to the self-degradation rates of 
ferrate(VI) in 2% acetonitrile solution; the kapp values were estimated to be less than 
0.5 and 0.05 M?1 s?1, respectively.  
3.3. Identification of oxidation products 
The test solution samples of each compound were treated by ferrate(VI) at two 
doses, and then analysed by LC-MS in ESI positive and/or negative mode under full 
MS scans. By comparing the total ion chromatograms (TICs) of the treated samples 
with the TICs of two blanks (ferrate(VI) and pharmaceuticals), any new peaks visible 
in the TICs of treated samples were then investigated further for OP identifications.  
The removal rates of target compounds by ferrate(VI) varied among the four 
compounds (Table S3, SM). It is worth noting that the removal of BZF by ferrate(VI) 
was very low (2–3%) and no OPs were found in the treated solutions. However, in 
treating test solution samples with initial concentrations of 10–100 ?g/L, up to 20% of 
BZF could be removed by 5 mg/L ferrate(VI). The extremely low removal rates of 
BZF obtained in this section might be explained by the following: 1) the minimal 
removal of BZF by ferrate(VI) was very likely attributed to the coagulation effect of 
ferric ions reduced from ferrate(VI); and 2) the test solutions in this section were 
stirred at 200 rpm constantly, which was not ideal for the formation and aggregation 
of flocs and hence reduced the coagulation effect substantially. 
A number of OPs were detected for SMX, DCF and CBZ in their specific test 
solutions. Most of the OPs for each compound were detected under both ferrate(VI) 
dose conditions. Moreover, the MS instrumental response for most of the detectable 
products at 10 mg/L ferrate(VI) was stronger than that at 5 mg/L (Table S4, SM), 
which further indicated that they were the OPs resulting from ferrate(VI) oxidation. 
Based on the measured m/z values, the best-fit chemical structures of such OPs were 
tentatively proposed by referring to prior knowledge, considering the molecular 
pattern of the target compounds and the mechanism of ferrate(VI) oxidation. 
Ferrate(VI) oxidation of organic compounds occurs via one/two-electron transfer, 
hydrogen abstraction or oxygen transfer [36], with great reactivity with electron-rich 
moieties such as olefins, phenols and amines [26]. 
 
3.3.1. SMX 
The analysis of SMX samples was conducted in ESI positive mode in the LC-
MS. Three OPs of SMX with m/z 269.8, 267.8 and 283.8 were found from the TIC 
chromatograms. SMX contains an aniline functional group and a five-member 
heterocyclic functional group, which are connected by a sulfonyl functional group at 
both sides. Both the aniline group and the heterocyclic group could be the attacking 
positions during ferrate(VI) oxidation [32]. The OPs of SMX with their probable 
structures are given in Table 2. The MW of SMX is 253; the increase of 16 atomic 
mass units (amu) in SMX-1 might be caused by a hydroxylation in the aniline ring of 
SMX [37]. Moreover, the replacement of amino group by an N=O bond yielded 
SMX-2 [38]. In addition, there were two probable isobaric compounds for the SMX 
OP with an m/z value of 283.8, shown as the OPs SMX-3a and SMX-3b [37]. 
 
Table 2 
OPs of SMX detected by LC-MS in positive mode. 
 
The pathways of SMX’s transformation during ferrate(VI) oxidation are 
presented in Fig. 3. The insertion of one oxygen atom resulted in the hydroxylation of 
the aromatic ring (SMX-1), though the precise position of the hydroxyl group could 
not be determined. The attack of ferrate(VI) might occur at the amino-N by hydrogen 
abstraction and oxygen insertion, yielding a nitroso-benzene derivative of SMX 
(SMX-2). The formation of nitroso OPs was also reported in the treatment of other 
sulfamide antibiotics by ferrate(VI) [17]. Further hydroxylation of the aromatic ring in 
SMX-2 could take place, which may have led to the formation of SMX-3a. In addition, 
the amino moiety might also be oxidised into a nitrobenzene derivative of SMX via 
oxygen transfer (SMX-3b). The formation of nitrobenzene derivatives via oxygen 
transfer is a common pathway for the transformation of anilines [39].  
 
 
Fig. 3. Pathways of SMX degradation by ferrate(VI). 
 
3.3.2. DCF 
The concentration of DCF could be reduced to less than its limit of detection 
(LOD) in LC-MS when the applied ferrate(VI) was 10 mg/L. Four OPs of DCF were 
found in the solutions treated by ferrate(VI). Specifically, two OPs were found in ESI 
negative mode with m/z values of 284.1 and 279.8, while another two OPs were 
detected in ESI positive mode with m/z values of 152.1 and 309.7. Probable chemical 
structures were proposed in Table 3 for these OPs of DCF based on the literature [e.g., 
40]. Specifically, DCF-1 was a mono-aromatic product, DCF-2 was an imino-quinone 
derivative of DCF, and DCF-3 was also an imino-quinone derivative with 
decarboxylation of the lateral chain. On the other hand, DCF-4 was formed by di-
hydroxylation of both aromatic rings with the lateral chain also replaced by a 
hydroxyl group.  
 
Table 3 
OPs of DCF detected by LC-MS in ESI positive and negative modes. 
 
The proposed pathways of DCF during ferrate(VI) treatment are given in Fig. 
4. DCF-1 is a mono-aromatic compound that was formed by the cleavage of the N-C 
bond between two aromatic rings. A N-C breakage was also observed in the oxidation 
of glycine by ferrate(VI) [41]. The formation of DCF-2 might occur via a major DCF 
intermediate, 5-hydroxy-DCF, which is commonly generated during oxidation [40]. 
The –OH and –NH2 groups in the aromatic ring of 5-hydroxy-DCF are electron-
donating groups, which increased the electron density in the ortho- and para- positions 
of the aromatic ring and therefore attracted ferrate(VI)’s attacks on such groups and 
formed the keto-derivative DCF-2 via hydrogen abstraction. Hydrogen abstraction is 
considered to be the pathway for the oxidation of aqueous phenol to quinone by 
ferrate(VI) [42]. The carboxyl group of DCF-2 could be further oxidised with the loss 
of a C=O carbonyl group, yielding another OP, DCF-3. Moreover, the hydroxylation 
on both aromatic rings of DCF and the loss of a C2H2O group led to the formation of 
DCF-4. However, based on the available information, it was not possible to determine 
the precise positions on the aromatic rings where the hydroxylation occurred. 
 
 
Fig. 4. Pathways of DCF degradation by ferrate(VI). 
 
3.3.3. CBZ 
The CBZ molecule contains an olefinic double bond, which is an electron-rich 
moiety and has been reported as the main attacking site during chemical oxidation 
processes [43]. In the test solution samples analysed by LC-MS in positive mode, 39% 
of CBZ was reduced by 10 mg/L ferrate(VI), and three OPs of CBZ with m/z values 
252.7, 266.7 and 250.8 were detected. The probable molecular formulas and chemical 
structures of these three OPs are presented in Table 4, by considering previous 
knowledge of CBZ degradation [44]. CBZ-1 had a nominal MW of 252, and the 
addition of 16 amu from CBZ was equivalent to the addition of one oxygen atom. The 
proposed structure of CBZ-1 was 10, 11-epoxy-CBZ, which is also a major metabolite 
of CBZ during bio-degradation [45]. There were two probable structures for the 
second OP with an m/z value of 266.7, marked as CBZ-2a and CBZ-2b. These two 
products appeared to result from the opening and subsequent re-organisation of the 
heterocyclic ring. The formation of CBZ-3 also appeared to involve a series of re-
organisations of the heterocyclic ring. 
 
Table 4 
OPs of CBZ detected by LC-MS in ESI positive mode. 
 
The pathways of CBZ degradation during ferrate(VI) treatment are proposed 
in Fig. 5. Ferrate(VI) attacked the olefinic moiety on the central heterocyclic ring, 
resulting in the insertion of an oxygen atom and the formation of an epoxy derivative, 
CBZ-1. Further reactions of ferrate(VI) with the epoxy moiety led to the opening of 
the heterocyclic ring and produced a hypothesised intermediate with aldehyde and 
carboxyl moieties. This intermediate during CBZ degradation has also been proposed 
elsewhere [43]. Then, the amine moiety of the urea group (–RR’NCONH2) in the 
intermediate reacted with either the carboxyl or the aldehyde moiety, which led to the 
formation of intra-molecular cyclisation products: CBZ-2a and CBZ-2b, respectively. 
The proposed degradation scheme of CBZ by ferrate(VI) is in agreement with the 
results of another study [46]. Moreover, the further loss of an oxygen atom from 
CBZ-2a yielded CBZ-3. 
 
 
Fig. 5. Pathways of CBZ degradation by ferrate(VI). 
 
4. Conclusions 
The results of the treatment of selected pharmaceuticals in test solution samples 
demonstrated that ferrate(VI) can effectively remove SMX, DCF and CBZ at a 
ferrate(VI) dose of 3 mg/L. In contrast, the removal of BZF by ferrate(VI) was less 
than 25% under the applied experimental conditions. Generally, increasing the dose of 
ferrate(VI) improved the treatment performance, while the influence of the solution 
pH on ferrate(VI) performance varied among different target compounds.  
The apparent second-order rate constants of ferrate(VI) with SMX, DCF and 
CBZ at pH 8 and pH 9 were established at 20 °C; the rate constants at pH 8 (e.g., kSMX 
= 360 ± 17 M?1 s?1) were higher than that at pH 9 (e.g., kSMX = 1.26 ± 0.02 M?1 s?1). 
Being consistent with relatively poor BZF removal, the apparent second-order rate 
constants of ferrate(VI) with BZF were less than 0.5 M?1 s?1 at pH 8 and pH 9. 
Moreover, a number of oxidation products (OPs) of SMX, DCF and CBZ during 
ferrate(VI) oxidation were detected, and their degradation pathways were tentatively 
proposed. However, no OPs of BZF were detected due to poor degradation by the 
ferrate(VI) oxidation.  
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Fig. 1. The effect of ferrate(VI) dose and solution pH on the removal of 
pharmaceuticals from a mixed-compound solution (initial concentration of 100 ?g/L) 
(a) BZF; (b) SMX; (c) DCF; and (d) CBZ. 
 
 Fig. 2. The effect of ferrate(VI) dose and solution pH on the removal of 
pharmaceuticals from a mixed-compound solution (initial concentration of 10 ?g/L) 




Fig. 3. Pathways of SMX degradation by ferrate(VI). 
 




Fig. 5. Pathways of CBZ degradation by ferrate(VI). 
Table 1 
Apparent second-order rate constants for the reactions of ferrate(VI) with selected 
pharmaceuticals. 
Compound 
kapp (M?1 s?1) 
pH 8 pH 9 
SMX 360 ± 17 1.26 ± 0.02 
DCF 12.48 ± 0.98 0.60 ± 0.01 
CBZ 23.83 ± 0.52 1.09 ± 0.11 
BZF <0.5 <0.05 
 
  
 Table 2 







SMX-1 269.8 269 C10H11N3O4S 
 











 Table 3 
OPs of DCF detected by LC-MS in ESI positive and negative modes. 























 Table 4 
OPs of CBZ detected by LC-MS in ESI positive mode. 
OP m/z Nominal MW Molecular formula Probable structure 
CBZ-1 252.7 252 C15H12N2O2 
 
CBZ-2a 
266.7 266 C15H10N2O3  
CBZ-2b 
 
CBZ-3 250.8 250 C15H10N2O2 
 
 
